TEL AVIV, Israel– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. Angus Grant, Ph.D., as EVP, Business Development. Dr. Grant will begin his employment on August 1, 2023, and will be based out of Teva’s US headquarters in Parsippany, NJ.
Dr. Grant joins Teva with over 25 years of experience in the global pharmaceutical and biotech industry, with an exceptional track record across a variety of fields including Business Development, R&D and Regulatory Affairs. Most recently, Dr. Grant served as the Chief Business Executive at BeiGene, overseeing business development, clinical and business insights and valuation, investments and collaborations, and alliance management. Before his tenure at BeiGene, Dr. Grant served as CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Earlier in his career, Dr. Grant spent 12 years at Celgene, serving in various leadership roles including Corporate Vice President of Business Development, and Vice President, Regulatory Affairs.
Richard Francis, Teva’s President and CEO said: “We are pleased to welcome a leader of Angus caliber to our executive team at Teva. With a distinguished career spanning over more than two and a half decades in the global pharmaceutical and biotech industry, his breadth of experience and demonstrated expertise in business development, innovative R&D, and scientific affairs will be a significant asset to our organization.
Mr. Francis continued: “These are exciting times at Teva, as we embark on our Pivot to Growth strategy, a crucial element of which involves amplifying our innovation through our already promising pipeline as well as fortifying our business development endeavors. I have full confidence in Angus leadership and firmly believe that he is exceptionally positioned to lead the business development efforts during this era of transformation. His contributions will be instrumental in driving external innovation, fostering collaborations across academia, biotech, and pharmaceutical sectors, and enhancing Teva’s momentum in bringing innovative therapies to patients worldwide.”
Dr. Grant stated, “I am thrilled to be joining Teva’s executive leadership team and am inspired by Teva’s purpose and strategy to drive growth by stepping up and leaning more into innovation. I am looking forward to work with the extended Teva team and leading the excellent business development team, to drive innovation and to partner with the best minds in academia and the industry to bring meaningful impact and value for patients worldwide and for Teva.”
Angus has held executive leadership positions at BeiGene, a global, commercial-stage biotechnology company, where he led Strategy and Partnering. Angus also served as CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease and in senior leadership positions at Celgene. Earlier in his career, Dr. Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham. After completing his PhD in Anatomy/ Immunology, Angus joined a clinical laboratory within the NIH prior to joining the FDA where he focused on cell and gene therapy IND processing.
In 2006, Angus joined Celgene and held various leadership over his 12 years, including Corporate VP Business Development. Angus led deals ranging from R&D and commercialization collaborations to early equity investments, supply collaborations, M&A such as $9B Juno acquisition in 2018, and licensing both globally and regionally.
Angus departed Celgene to serve as CEO of Dementia Discovery Fund (DDF), inspired by their mission to invest in and build the early-stage biotech companies most likely to develop transformative treatments for neurodegenerative diseases, to the benefit of the millions of people suffering from this health crisis of the 21st century that has longed lacked effective treatments.
Dr. Grant received his undergraduate degree from the University of Richmond and a Ph.D. in anatomy and immunology from the Medical College of Virginia, and he completed his postdoctoral training at the National Cancer Institute. Dr. Grant currently serves as the Chairman of the Board for Toronto Innovation and Acceleration Partners. He is a published scientist, co-authoring more than 15 articles in peer-reviewed scientific journals.
